AKT1 and ovarian cancer: In the present study, we elucidated the mechanisms by which COL11A1 promotes cancer cell sensitivity to anticancer drugs, and we observed that, in ovarian cancer cells, chemoresistance developed via activation of the Akt/c/EBPβ pathway in concert with increased PDK1 degradation (Fig. 6C).